

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical suspension formulation comprising
 - a. particles of formoterol or a pharmaceutically acceptable salt,~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
 - b. particles of ciclesonide or a pharmaceutically acceptable salt,~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation and
 - c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.
2. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt,~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
 - b. particles of micronized ciclesonide or a pharmaceutically acceptable salt,~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
 - c. ethanol,

- d. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - e. optionally further comprising a surfactant.
- 3. (Previously presented) The pharmaceutical suspension formulation according to claim 1 containing less than 3% by weight of ethanol.
- 4. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising
 - a. particles of micronized formoterol, or a pharmaceutically acceptable salt, ~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
 - b. particles of micronized ciclesonide or a pharmaceutically acceptable salt, ~~solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
 - c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and
 - d. a surfactant.
- 5. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises R,R-formoterol.

6. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises formoterol fumarate dihydrate.
7. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises oleic acid as surfactant.
8. (Currently amended) The pharmaceutical suspension formulation according to claim [[1]] 7 which comprises about 0.001 to 0.1 % (w/w) of oleic acid.
9. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises HFA 227 as propellant.
10. (Currently amended) The pharmaceutical suspension formulation according to claim 1 further comprising disodium chromoglycate at a concentration which is not therapeutically and/or prophylactically active.
11. (Previously presented) The pharmaceutical suspension formulation according to claim 1, which is administered in a once daily dosing regimen.